Skip to main content

Table 3 Multivariable analysis of transplants outcomes according to donor type

From: Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT

 

MSD

MUD

Haplo

Outcome

Reference

HR

95% CI

p

HR

95% CI

p

Acute GvHD

 Grades II–IV

1

1.42

0.92–2.19

0.11

1.6

1.08–2.37

0.02

 Grades III–IV

1

1.22

0.56–2.64

0.61

1.76

0.92-3.37

0.09

Chronic GvHD

 Overall

1

0.97

0.64–1.46

0.88

1.22

0.84–1.76

0.92

 Extensive type

1

0.98

0.57–1.7

0.95

0.87

0.53–1.42

0.57

NRM

1

1.38

0.73–2.6

0.3

2.6

1.5–4.49

< 0.001

RI

1

0.8

0.54–1.17

0.24

0.67

0.48–0.93

0.02

LFS

1

0.93

0.68–1.29

0.67

1.07

0.82-1.4

0.6

OS

1

0.91

0.64–1.31

0.62

1.17

0.86–1.59

0.32

GRFS

1

1.01

0.76–1.34

0.94

1.03

0.82–1.31

0.8

  1. GvHD graft-versus-host disease, CI confidence interval, NRM non-relapse mortality, RI relapse incidence, LFS leukemia-free survival, OS overall survival, GRFS graft-versus-host disease and relapse-free survival